Phaseline

Companies › Genor Biopharma

Genor Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GB491–Phase 3Breast CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05851014GB491Phase 3Breast CancerOncologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.